Biotech firm Pulmocide has received £17m ($27.84m) in series A backing as the Imperial College London (ICL) spin-out heads to the institution’s BioIncubator.

ICL’s tech transfer unit Imperial Innovations invested £4.25m in the round, and was joined by a venture consortium of SV Life Sciences, Fidelity Biosciences, and pharmaceutical giant Johnson & Johnson’s corporate venturing unit J&J Development Corporation.

Pulmocide will be focused on the discovery and development of the next-generation of inhaled medicines for the treatment of infections of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?